BioCatalyst

KB707, Pembrolizumab (KEYTRUDA®), Chemotherapy, Docetaxel — catalyst calendar

1 verified catalyst event(s) referencing KB707, Pembrolizumab (KEYTRUDA®), Chemotherapy, Docetaxel, each linked to its official source. Verified as of 2026-10-02.

Upcoming

DateEventCompanyDrugOfficial source & verification
2027-02 (month)
in 4mo
ESTIMATED
 READOUT
A Study Assessing KB707 for the Treatment of Advanced Solid Tumor Malignancies A
Phase 1/2 · Lung Cancer, Non-small Cell, Lung Cancer Metastatic
 KRYS Krystal Biotech, Inc. KB707, Pembrolizumab (KEYTRUDA®), Chemot ClinicalTrials.gov ↗
✓ Source-checked 2026-10-02
Sponsor-projected date — can change
Disclaimer. Bio Catalyst Calendar is a public-events data calendar. Every date is sourced and linked to an official record (ClinicalTrials.gov, FDA / Federal Register, openFDA). It is scheduling and reference data only — NOT investment advice, a recommendation, or a buy/sell signal. Dates set by sponsors and the FDA can change; always confirm against the linked official source.